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C hronic kidney disease (CKD) affects more than 10% of the world’s population; it is particularly 
common in the elderly and in the presence of comor-
bidities such as hypertension,  diabetes,  and hyperlip-
idemia [1].  When these underlying comorbidities and 
risk factors are not adequately controlled,  CKD often 
results in end-stage renal disease (ESRD) [2].  The role 
of metabolic abnormalities in the progression of kidney 
disease is thus receiving increasing attention.  Progres-
sive kidney disease is often accompanied by histopatho-
logic evidence of glomerulosclerosis and tubulointersti-
tal alterations including tubular atrophy and interstitial 
fibrosis [3 , 4].  Such changes are thought to be the 
results of a loss of renal capillaries and are known to be 
highly predictive of the subsequent deterioration of 
renal function and CKD progression [5].  Indeed,  sev-
eral angiogenesis-related factors such as vascular endo-
thelial growth factor (VEGF)-A,  soluble Flt-1,  angio-
poietins,  and vasohibin-1 (VASH-1) have been shown 
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Several angiogenesis-related factors are known to play important roles in the pathogenesis of kidney disease.  
Vasohibin-2 (VASH-2) was recently reported as a novel proangiogenic factor.  Although VASH-2 was demon-
strated to accelerate tumor angiogenesis,  its roles in non-tumor processes including renal disease have not been 
well elucidated yet.  Here,  we performed a retrospective study including an immunohistochemical analysis of 
human kidney biopsy specimens from 82 Japanese patients with a variety of kidney diseases,  and we evaluated 
the correlations between the immunoreactivity of VASH-2 and the patients’ clinicopathological parameters.  
VASH-2 immunoreactivity was detected in varying degrees in renal tubules as well as in peritubular capillaries 
and vasa recta.  The cortical and medullary tubule VASH-2+ scores were correlated with the presence of hyper-
tension,  and the medullary tubule VASH-2+ score was significantly correlated with the blood glucose (p= 0.029,  
r= 0.35) and hemoglobin A1c levels (p= 0.0066,  r= 0.39).  Moreover,  decreased VASH-2+ scores in the vasa recta 
were associated with reduced renal function (p= 0.0003).  These results suggest that VASH-2 could play an 
important role in the pathogenesis of renal diseases,  and that VASH-2 is closely associated with hypertension 
and impaired glucose tolerance.
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to be related to the severity of interstitial fibrosis in 
CKD [6-9].
VEGF-A is a proangiogenic factor that is expressed 
mainly by podocytes and tubular epithelial cells in the 
normal kidney [6],  and it is upregulated in renal 
tubules in patients with early stage IgA nephropathy 
with peritubular capillary loss [10].  VASH-1 is an 
endogenous angiogenesis inhibitor that is up-regulated 
by VEGF-A in endothelial cells in an autocrine man-
ner; it acts as a negative feedback regulator of angio-
genesis [11].  The therapeutic efficacy of VASH-1 has 
been demonstrated in animal models of malignancy 
[12 , 13],  atherosclerosis [14],  and diabetic nephropa-
thy [15 , 16],  and we recently demonstrated an associa-
tion between elevated urinary and plasma levels of 
VASH-1 and the progressive decline of the renal func-
tion in patients with CKD [17].
Plasma VASH-1 levels were also shown to be nega-
tively correlated with blood pressure and positively 
correlated with the mean percentage of glomeruli with 
crescent formation in renal biopsies [18].  We have also 
observed that VASH-1 is expressed in renal endothe-
lial/mesangial cells,  crescentic lesions and interstitial 
inflammatory cells,  and that there is a significant asso-
ciation between the number of VASH-1-positive cells 
with crescent formation and interstitial infiltration in 
crescentic glomerulonephritis [17].
Vasohibin-2 (VASH-2) is a homologue of VASH-1 
that is generally considered to be an endogenous proan-
giogenic factor [11 , 19 , 20].  VASH-2 was first identified 
in a mouse model of subcutaneous angiogenesis as in 
infiltrating bone marrow-derived mononuclear cells at 
the sprouting point of neo-vessels [21],  and it has been 
shown to be expressed in various tumor tissues includ-
ing serous ovarian adenocarcinoma [22],  hepatocellu-
lar carcinoma [23],  and gastrointestinal carcinoma [24].  
Most of the published studies on VASH-2 have focused 
on VASH-2 expression in tumor angiogenesis [25-27],  
but the possible roles of VASH-2 in non-tumor patho-
logical conditions have not been determined.
Considering its homology to VASH-1 (an important 
factor in renal diseases),  we have looked for any possi-
ble association of VASH-2 in human kidney diseases.  In 
the present study,  we examined kidney biopsy speci-
mens from patients with kidney disease to determine 
the specimens’ VASH-2 expression,  and we examined 
the correlations between renal VASH-2 immunoreac-
tivity and various clinicopathological parameters.
Methods
Study design. We conducted a retrospective 
review of the cases of patients who had undergone a 
renal biopsy at Okayama University Hospital during the 
years 2007-2009 and 2014-2015.  Written informed 
consent for the use of their specimens was obtained 
from all patients,  and the study was approved by the 
Institutional Ethical Review Board of Okayama 
University Hospital (No. 471,  Oct.  23,  2007 and No. 
2063,  May 22,  2014).  We reviewed the clinical charts of 
these patients to examine the relevant clinical charac-
teristics that are generally known to affect the prognosis 
of renal or cardiovascular diseases.  Thirteen clinical 
parameters were considered: age,  gender,  body mass 
index (BMI),  blood pressure,  creatinine (Cr),  Cr-based 
estimated glomerular filtration rate (eGFR) [28],  blood 
urea nitrogen (BUN),  proteinuria,  uric acid (UA),  
phosphorus (P),  total cholesterol (T-Cho),  HDL cho-
lesterol (HDL-C),  LDL cholesterol (LDL-C),  triglycer-
ide (TG),  post-prandial plasma glucose (PPG),  and 
hemoglobin A1c (HbA1c; based on the National 
Glycohemoglobin Standardization Program value).  The 
diagnostic criteria for the clinical entities were as fol-
lows:
・Hypertension: systolic blood pressure (SBP) 
≥ 140 mmHg,  diastolic blood pressure (DBP) 
≥ 90 mmHg,  or on antihypertensive medications
・Diabetes mellitus: HbA1c ≥6.5%,  PPG ≥200 mg/
dL,  or on antidiabetic medications
・Dyslipidemia: T-Cho ≥220 mg/dl, LDL-C ≥140 mg/
dl, HDL-C ≤40 mmHg, or on antilipidemic medi-
cations
Biopsy specimens were stained and semi-quantita-
tively scored to assess renal histological alterations and 
immunostained to investigate the distributions of 
VASH-1 and VASH-2.  In addition,  paraffin-embedded 
normal kidney tissues were obtained from three 
patients who had undergone a surgical excision of 
localized renal cell carcinoma containing distant normal 
portions of the kidneys.
Histological scoring. Formalin-fixed,  paraffin- 
embedded sections were stained with periodic acid-
Schiff (PAS),  periodic acid-methenamine-silver (PAM),  
and Masson’s trichrome for light microscopic observa-
tion.  The histological parameters are based on the 
Oxford classification of IgA nephropathy [29].  Renal 
histological alterations were semi-quantitatively evalu-
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ated by scoring as follows [17 , 30].  Mesangial hypercel-
lularity and mesangial sclerosis scores: 0 = none,  
+1 = 1-25%,  +2 = 26-50%,  +3 = 51-75%,  +4 = 76-100% 
of the glomerulus.  Interstitial cell infiltration,  intersti-
tial fibrosis and tubular atrophy scores: 0 = none,  
+1 = mild,  +2 = moderate,  +3 = severe.  Vascular sclero-
sis scores: 0 = none,  +1 = mild,  +2 = severe.  The mean 
percentage of glomeruli with crescent formation and 
that of global sclerosis were also deter-mined.  The his-
tological evaluation was performed by 2 independent 
certified nephrologists.
Immunohistochemistry. Immunohistochemistry 
was performed as previously described [17 , 31 , 32].  
Following the deparaffinization and hydration of for-
malin-fixed,  paraffin-embedded 4-μm-thick sections,  
antigen retrieval was performed by boiling the sections 
in a hot bath in the target retrieval solution (Dako,  
Glostrup,  Denmark),  pH 9.0,  at 98°C for 40 min.  The 
following primary antibodies were used: (1) monoclo-
nal mouse anti-human VASH-1 (clone 4E12; 2 μg/mL) 
[15 , 33] and (2) monoclonal mouse anti-human VASH-2 
(clone 1760; 1 μg/mL) [33 , 34].  Both of these antibod-
ies were provided by the Institute of Development,  
Aging,  and Cancer,  Tohoku University; their specific-
ity on cancer cells was confirmed in human tissue spec-
imens [33 , 34].
The samples were washed with phosphate-buffered 
saline three times,  and secondary detection was per-
formed using a diaminobenzidine-based detection kit 
(EnVision+ system,  Dako) according to the manufac-
turer’s instructions.  Sections were counterstained with 
hematoxylin.  The immunohistochemistry sections were 
then descriptively reviewed to assess the localization 
and distribution of VASH-1 and VASH-2 staining.  
Sections were also semi-quantitatively scored for 
VASH-2-positive staining.  Specifically,  VASH-2+ cells 
in the renal medulla (tubules and vasa recta [VR]) and 
cortex (tubules,  glomeruli,  and peritubular capillaries 
[PTCs]) were determined using the following criteria 
[17 , 30]:
・Tubule score = the mean of % (none or score 1-3) 
× the intensity (score 1-3) in each 200 ×  field
・VR score = the mean of the number of VASH-2+ 
lumens of VR with VASH2+ cells in each 200 ×  
field
・PTC score = the mean of the number of lumens of 
PTC with VASH2+ cells in each 200 ×  field
・Glomerular score = the mean of % (none or score 
1-4) in each glomerulus
Statistical analysis. As the data were categorical 
(ranked) in nature,  non-parametric tests were used for 
comparisons.  Spearman’s rank order test,  the Steel test 
statistics,  and the Mann-Whitney U-test were used as 
appropriate.  All analyses were performed using JMP® 
11.1.1 Microsoft Excel software for Mac 2011,  ver.  
14.6.4.
Results
Patient characteristics. A total of 82 patients 
with renal dysfunction were included in the study 
(Table 1).  The patients were generally healthy with rel-
atively well-controlled hypertension (n = 52),  diabetes 
mellitus (n = 15),  dyslipidemia (n = 59) and without 
extreme obesity (mean BMI,  22.2).  Daily proteinuria 
varied among the patients,  ranging from 0.29 to 
2.89 g/day (mean,  0.81 g/day).  On the basis of the 
World Health Organization (WHO) clinical classifica-
tion of renal diseases,  the majority of the cases were 
chronic glomerulonephritis (52.4%),  followed by 
nephrotic syndrome (29.3%) and rapidly progressive 
glomerulonephritis (13.4%).
In terms of pathological diagnosis,  the majority of 
the cases were mesangial proliferative nephritis (32.9%) 
including IgA nephropathy,  followed by minimal 
change disease (MCD) (15.9%),  and secondary focal 
segmental glomerulosclerosis (FSGS) and nephroscle-
rosis (8.43-12.0%).
Renal distribution of VASH-2. Of the 82 biopsy 
specimens,  81 specimens included the renal cortex and 
51 included the renal medulla.  Immunoreactivity for 
VASH-2 was not observed in the glomeruli in any of the 
81 specimens from renal disease patients (Fig. 1A).  
VASH-2+ cells were observed in PTCs (Fig. 1B; 50/81 
specimens),  VR (Fig. 1C; 38/51 specimens) and both 
medullary and cortical tubules (Fig. 1C,  38/51 speci-
mens; Fig. 1D; 37/51 specimens).
In the control kidney specimens,  VASH-2+ cells were 
similarly observed in the VR and some PTCs,  but the 
tubular VASH-2 staining was weak (Fig. 1E , F),  sug-
gesting that VASH-2 is present mainly in the VR in the 
basal condition and that tubular staining could be 
inducible in some renal diseases.  Because the intensity 
of VASH-2 staining on the PTCs,  the VR and the renal 
tubules showed wide variation among the specimens,  
we evaluated the intensity of VASH-2 staining using a 
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semi-quantitative scoring system.  The VASH2+ scores 
on the PTCs were lower,  with an exceptionally wide 
range (median 0.0; range 0-10.59).  The tubular 
VASH2+ scores were generally higher in the renal 
medulla than in the cortex (median 0.75; interquartile 
range [IQR] 0.0-1.33 vs. 0.17; IQR 0.0-1.0).  The 
VASH2+ scores on the VR were the highest among the 
positive regions (median 10.89; IQR 0.0-24).
Correlation between VASH-2+ scores and histologi-
cal parameters. The histological scoring (mean;  
range) showed variable degrees of renal pathology in the 
form of mesangial hypercellularity (0.167; 0-0.383),  
mesangial sclerosis (0.100; 0-0.357),  crescent forma-
tion (0.0; 0-0.021),  global sclerosis (0.150; 0-0.295),  
cell infiltration (1; 0-1),  interstitial fibrosis (1; 1-2),  
tubular atrophy (1; 0-2),  and vascular sclerosis (1; 0-1).
As shown in Table 2,  none of these histological 
scores including tubular atrophy and interstitial fibrosis 
were significantly correlated with VASH-2+ scores on the 
PTCs,  VR,  or cortical and medullary tubules.  However,  
the presence of a histologically established diagnosis of 
diabetic nephropathy but not IgA nephropathy was sig-
nificantly correlated with the cortical renal tubule 
VASH-2+ scores,  and this presence tended to be associ-
ated with the medullary tubule VASH-2+ scores (Table 2 
and Fig. 2).
Correlation between VASH-2+ scores and clinical/
laboratory parameters. We next examined whether 
the VASH-2+ scores were associated with clinical or lab-
oratory parameters (Table 3).  VASH-2+ scores on the 
medullary tubules were significantly correlated with age,  
PPG and the HbA1c level (Table 3),  whereas the 
VASH-2+ scores on the cortical tubules showed no asso-
ciation with theses parameters.  With the use of 
Spearman’s rank order test,  it was revealed that the 
levels of PPG and HbA1c rose (that is,  as the patients’ 
glucose intolerance exacerbated),  the medullary tubule 
VASH-2+ scores increased (Fig. 3A , B).  Elevated SBP 
was significantly correlated with the increase in the cor-
tical tubule VASH-2+ score but not the medullary tubule 
scores (Fig. 4A , B).
Decreased eGFR values tended to be associated with 
lower VASH-2 scores on the VR,  but this association 
did not reach statistical significance (Fig. 4C).  
Considering the fact that the majority of the patients 
included in this study had well-controlled blood pres-
sure and normal renal function,  we divided the patients 
into subgroups with or without hypertension or renal 
372 Arata et al. Acta Med.  Okayama　Vol.  71,  No.  5
Table 1　 The 82 patientsʼ clinical,  laboratory and histological 
characteristics
Clinical characteristics
Age (y) 48.5 [32.0-64.3]
Gender (male/female; n) 37/45
Hypertension,  n (%) 52 (63.4)
Diabetes mellitus,  n (%) 15 (18.3)
Dyslipidemia,  n (%) 59 (72.0)
BMI (kg/m2) 22.2 [20.1-25.7]
SBP (mmHg) 130 [110-141]
DBP (mmHg)  78 [68-89]
Laboratory parameters
Hemoglobin (g/dL) 13.4 [12.0-14.7]
Phosphorus (mg/dL)  3.5 [3.0-3.8]
Uric acid (mg/dL)  5.7 [4.6-7.1]
eGFR (mL/min/1.73 m2) 69.0 [46.0-91.8]
eGFR <60,  n (%) 21 (25.6)
Daily proteinuria (g/day) 0.784 [0.294-2.99]
PPG (mg/dL) 106.0 [91.5-136.5]
HbA1c (%) 5.7 [5.4-6.2]
T-Cho (mg/dL) 212 [172-251]
LDL-C (mg/dL) 129 [90.0-154.5]
HDL-C (mg/dL)  60 [43-76.5]
TG (mg/dL) 139 [93.5-213]
Clinical classiﬁcation (WHO)
CGN,  n (%) 43 (52.4)
APHS,  n (%)  4 (4.9)
NS,  n (%) 24 (29.3)
RPGN,  n (%) 11 (13.4)
Pathological classiﬁcation
MPN,  n (%) 27 (32.9)
MCD,  n (%) 13 (15.9)
Secondary FSGS and 
nephrosclerosis,  n (%) 10 (12.2)
MN,  n (%)  8 (9.8)
NCGN,  n (%)  7 (8.5)
DMN,  n (%)  4 (4.9)
Others,  n (%) 14 (17.1)
Values for continuous variables are given as median [interquartile 
range].  Values for categorical variables are given as number (per-
centage).  APHS,  asymptomatic proteinuria and hematuria syn-
drome; BMI,  body mass index; CGN,  chronic glomerulonephritis;  
DBP,  diastolic blood pressure; DMN,  diabetic nephropathy;  
FSGS,  focal segmental glomerulosclerosis; HDL-C,  high-density 
lipoprotein cholesterol; LDL-C,  low-density lipoprotein cholesterol;  
MCD,  minimal change disease; MN,  membranous nephropathy;  
MPN,  mesangial proliferative nephritis; NCGN,  necrotizing and 
crescentic glomerulonephritis; NS,  nephrotic syndrome; PPG,  
post-prandial plasma glucose; RPGN,  rapidly progressive glomeru-
lonephritis; SBP,  systolic blood pressure; T-Cho,  total lipoprotein 
cholesterol; TG,  triglycerides.
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Table 2　 Correlation between VASH-2+ scores and histological parameters
PTC score Cortical tubule score VR score Medullary tubule score
r p r p r p r p
%Mesangial hypercellularity －0.0704 0.7065 0.1960 0.2906 －0.0347 0.8089 －0.1601 0.2617
%Mesangial sclerosis －0.3416 0.0600 0.3344 0.0659 －0.0599 0.6761 0.0978 0.4947
%Crescent formation 0.1509 0.4178 0.0954 0.6098 0.0037 0.9794 －0.2579 0.0677
%Global sclerosis －0.2451 0.1838 －0.0482 0.7969 0.2323 0.101 0.0727 0.6123
Cell inﬁltration －0.3376 0.0633 0.1545 0.4065 0.0715 0.6179 0.2011 0.157
Interstitial ﬁbrosis －0.3052 0.0951 0.2112 0.2540 0.0674 0.6384 0.2289 0.1062
Tubular atrophy －0.2340 0.2052 0.3088 0.0910 0.0857 0.55　 0.2748 0.0510
Arteriosclerosis －0.2224 0.2292 0.2086 0.2600 －0.1478 0.3008 0.0878 0.5403
DMN or not 0.2647 0.0035＊ 0.3326 0.0517
IgAN or not 0.8601 0.9398 0.7823 0.5789
DMN; diabetic nephropathy,  IgAN; IgA nephronpathy. ＊p＜0.05.
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Fig. 1　 Immunochemistry of VASH-2 in human kidney biopsy specimens.  Representative VASH-2 immunohistochemical images from 
patients with kidney diseases.  A,  Glomerulus in obesity-related nephropathy; B,  Peritubular capillaries in IgA nephropathy (IgAN); C,  
Vasa recta (VR) and medullary tubules in IgAN; D,  Cortical tubules in membranousnephropathy.  Immunoreactivity of VASH-2 is observed 
in endothelial cells of a PTC (arrows),  the VR (dots),  and cortical (asterisks) and medullary (arrowheads) tubules,  at various intensities.  
In control kidney (E,  F),  VASH-2 positive cells were seen mainly in the VR (dots) and partially in PTCs (arrow).  Tubular staining for 
VAHS-2 (arrowhead) was detected weakly in only a small fraction.   Scale bars: 100 μm.
dysfunction (defined as eGFR ≤ 60 mL/min/1.73 m2).  
The subgroup analysis revealed that the cortical and 
medullary tubule VASH-2+ scores were significantly 
higher in the patients with hypertension (Fig. 5A , B).  In 
addition,  VASH-2+ scores on the VR were significantly 
lower in the patients with renal dysfunction (Fig. 5C).
Correlation between VASH-2+ score and VASH-1 
staining in kidney. Consistent with our previous 
report about patients with CKD [17],  immunoreactiv-
ity for VASH-1 was observed in glomeruli (some 
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Table 3　 Correlation between VASH-2 scores and clinical/laboratory parameters
PTC score Cortical tubule score VR score Medullary tubule score
r p r p r p r p
Age (yrs) －0.2987 0.1026 0.0756 0.6862 －0.0456 0.7506 0.3466 0.0127＊
BMI (kg/m2) －0.3533 0.0555 －0.0982 0.6056 －0.0618 0.6665 0.2299 0.1046
SBP (mmHg) －0.4595 0.0106＊ 0.247 0.1883 0.1474 0.3018 0.2471 0.0804
Hb (g/dL) －0.056 0.7689 －0.0331 0.862 0.0794 0.5798 0.1517 0.2881
P (mg/dL) 0.198 0.3126 －0.0482 0.8075 －0.2238 0.1305 －0.289 0.0488
UA (mg/dL) －0.3685 0.0451＊ 0.235 0.2113 0.0318 0.8284 0.0106 0.9425
eGFR (mL/min/1.73 m2) 0.2911 0.1121 －0.15 0.4205 －0.0189 0.8951 －0.2526 0.0738
UP (g/day) 0.009 0.9625 0.1263 0.5059 0.1306 0.3763 0.0249 0.8665
PPG (mg/dL) －0.0101 0.9585 0.1741 0.3663 0.1553 0.2918 0.387 0.0066＊
HbA1c (%) －0.0262 0.9011 0.0008 0.997 －0.0939 0.5644 0.3465 0.0285＊
T-Cho (mg/dL) 0.0508 0.7896 0.1379 0.4674 －0.1811 0.2082 －0.036 0.8042
LDL-C (mg/dL) 0.0611 0.7528 0.1639 0.3956 －0.1357 0.3577 －0.0718 0.6276
TG (mg/dL) －0.3448 0.067 0.1944 0.3122 0.1776 0.2222 0.0853 0.5603
BMI,  body mass index; eGFR,  estimated glomerular ﬁltration rate; Hb,  hemoglobin; LDL-C,  low-density lipoprotein cholesterol; P,  phos-
phorus; PPG,  post-prandial plasma glucose; SBP,  systolic blood pressure; T-Cho,  total lipoprotein cholesterol; TG,  triglycerides.; UA,  
uric acid; UP,  urinary protein.  ＊p＜0. 05.
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Fig. 2　 Subgroup analysis of VASH-2+ 
scores in the patients with and without 
diabetic nephropathy.  Comparison between 
the patients with DMN and those without 
DMN by Mann-Whitney test.  Among the 
VASH-2+ scores,  both the cortical and 
medullary tubule scores appear to be higher 
in DMN (p=0.0035 and p=0.0517,  respec-
tively).
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Fig. 4　 Correlation analysis of VASH-2 scores and blood pressure or renal function.  The correlations between the cortical tubule VASH-
2+ score and SBP (A),  between the medullary tubule VASH-2+ score and SBP (B),  and between the VR VASH-2+ score and eGFR (C) by 
Spearmanʼs rank order test.  SBP was signiﬁcantly correlated with the cortical tubule VASH-2+ score but not the medullary tubule VASH-2+ 
score.  eGFR tended to be inversely related with the VR VASH-2+ score,  but not signiﬁcantly so.  The r-values are Spearman correlation 
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Fig. 5　 Subgroup analysis of VASH-2+ scores in the patients with and without hypertension or reduced eGFR.  Comparison between the 
patients with and without hypertension (A,  B) or declined eGFR (C: ≤60 ml/min/1.73 m2) by the Mann-Whitney test.  Among the VASH-
2+ scores,  both the cortical and medullary tubule scores were signiﬁcantly higher in the patients with hypertension (p=0.00234 and 
p=0.0403,  respectively),  whereas the VR scores were lower in the patients with reduced eGFR (C).
Fig. 3　 Correlation analysis of VASH-2 
scores and glucose intolerance.  The cor-
relations between the medullary tubule 
VASH-2+ score and the post-prandial 
plasma glucose (PPG; A) or hemoglobin 
A1c (HbA1c; B) were evaluated by 
Spearmanʼs rank order test.  Both parame-
ters were signiﬁcantly correlated with the 
VASH-2+ scores.  The r-values are 
Spearman correlation coeﬃcients.
mesangial cells,  Fig. 6A),  renal cortex (endothelial cells 
and interstitial inflammatory cells,  Fig. 6B),  and 
medulla (VR endothelial cells,  Fig. 6C).  In the control 
kidneys,  VASH-1-positive endothelial cells were con-
firmed in peritubular capillaries (Fig. 6D) as shown 
previously [17].  We found no association between any 
of the VASH-2+ scores and the numbers of VASH-1+ 
cells (Table 4).
Renal survival analysis. We performed a Kaplan- 
Meier analysis of the deterioration in renal function 
(defined as > 30% reduction in the eGFR compared to 
baseline) according to VASH-2+ scores,  in order to 
evaluate the possible impact of VASH-2 on renal prog-
noses.  This analysis used the mean and 75th quartile 
values of the respective scores as the cutoffs.  In general,  
higher tubular VASH-2+ scores (> 75th quartile) espe-
cially in the medullary region (p = 0.0093) were signifi-
cantly associated with poorer outcomes over time 
(Fig. 7A-D).  Although the subgroup with reduced 
eGFRs tended to have lower in VASH-2+ VR scores 
(Fig. 5C),  neither higher nor lower VR scores seemed to 
be associated with a sequential reduction in renal func-
tion (Fig. 7E , F).  The PTC VASH-2+ scores as well 
seemed to show no obvious association with renal sur-
vival (data not shown).
Discussion
The results of this immunohistochemical analysis 
suggest that VASH-2 plays a significant role in human 
kidney diseases.  VASH-2-positive cells were not 
observed in glomeruli,  but they were observed in the 
VR and peritubular capillaries as well as renal tubules in 
patients with kidney disease.  Consistent with our 
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Table 4　 Correlation between VASH-2+ scores and VASH-1 staining
PTC score Cortical tubule score VR score Medullary tubule score
r p r p r p r p
VASH-1+ score of glomeruli －0.1536 0.4262 　0.1678 0.3841 －0.2001 0.2980 －0.0982 0.6125
VASH-1+ cells in cortex 　0.2933 0.1225 　0.1277 0.5091 －0.0971 0.6162 　0.0125 0.9485
VASH-1+ cells in medulla 　0.1242 0.6018 －0.0720 0.7631 －0.1979 0.4030 －0.3395 0.1431
Fig. 6　 Immunohistochemistry of the human kidney with 
VASH-1.  Representative VASH-1 immunohistochemical images 
from patients with IgA vasculitis kidney diseases.  A,  
Glomerulus; B,  Cortical region; C,  Medullary region.  
Immunoreactivity for VASH-1 was observed in some mesangial 
cells (asterisk,  A),  endothelial cells,  and interstitial inﬂamma-
tory cells in the cortex (arrows,  B),  and VR endothelial cells in 
the medulla (arrowhead,  C).  In the control kidney,  VASH-1 
staining was detected in endothelial cells (arrows,  D).  Scale 
bars: 100 μm.
results,  VASH-2 was previously shown to be expressed 
in blood vessels from human embryonic tissues,  espe-
cially in endothelium [11].
Interestingly,  we observed a correlation between 
renal tubular VASH-2 immunoreactivity and plasma 
glucose and HbA1c levels,  suggesting a relationship 
between VASH-2 expression and impaired glucose tol-
erance (IGT).  The VASH-2+ tubule scores were also 
higher in the diabetic nephropathy group.  Although 
these preliminary findings failed to demonstrate a cause 
and effect relationship between increased VASH-2 
immunoreactivity and IGT,  they suggest a potential 
role of hyperglycemia in inducing tubular VASH-2 
expression.  In diabetic nephropathy,  hyperglycemia 
causes increased oxygen consumption in the kidneys,  
leading to tissue ischemia and hypoxia-related injury 
that first affect the interstitial regions in the renal 
medulla due to lower blood flow,  before affecting glom-
eruli [35 , 36].  It was reported that in diabetic nephrop-
athy,  hyperglycemia-induced hypoxia promotes the 
gene expression of factors such as glucose transporter 1 
(GLUT-1) and VEGF,  which control energy metabo-
lism,  cellular proliferation/differentiation,  and angio-
genesis [37 , 38].  The preferential and higher expression 
of VASH-2 in the renal medulla observed in the present 
study suggests that VASH-2 could also play a similar 
role in diabetic nephropathy.
In this investigation,  VASH-2 immunoreactivity was 
detected in the VR and peritubular capillaries but not in 
glomerular capillaries.  This discrepancy cannot be 
explained on the basis of current knowledge about the 
regulatory mechanisms of VASH-2 gene expression.  
Considering the anatomy of the renal vasculature,  the 
VR and peritubular capillaries are more likely to 
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Fig. 7　 Renal survival analysis according to VASH-2+ scores.  The outcome is deﬁned as a ＞30% reduction in eGFR from the baseline 
within the follow-up duration of 100 months.  The renal survival in the subgroup above (solid line) and below (dotted line) each cutoﬀ is 
shown.  A,  B,  Cortical tubule VASH-2+ scores with the mean (0.134) and the 75th quartile (0.398) as the cutoﬀ,  respectively; C,  D,  
Medullary tubule VASH-2+ scores with the mean (0.74) and the 75th quartile (1.39) as the cutoﬀ,  respectively; E,  F,  VR VASH-2+ scores 
with the mean (0.844) and the 75th quartile (0.353) as the cutoﬀ,  respectively.  Overall,  there were no signiﬁcant associations between the 
subgroups regarding preserved renal function over time,  except for our ﬁnding that higher tubular VASH-2+ scores in medullary tubules are 
signiﬁcantly associated with poor outcome (p=0.0093).
become hypoxic compared to the glomeruli.  In addi-
tion,  whereas podocytes deliver a large amount of 
VEGF to endothelial cells in the glomeruli,  the VR and 
peritubular capillaries receive VEGF from surrounding 
tubular cells to a lesser extent [39].  Thus,  the VR and 
peritubular capillaries might require the angiogenic 
systems independent of VEGF in response to hypoxia.
Kimura et al.  reported that VASH-2 was expressed 
in bone marrow-derived mononuclear cells in a mouse 
model of subcutaneous angiogenesis [21].  However,  
VASH-2 staining was found in cancer cells but not 
interstitial mononuclear cells in human ovarian carci-
noma tissues [22].  These findings suggest that VASH-2 
expression on mononuclear cells could be detected only 
in the active process of angiogenesis induced by hypoxia.  
Indeed,  we did not detect VASH-2 immunoreactivity in 
the infiltrating mononuclear cells in the tubulointersti-
tial nephritis specimens.
We observed varying distributions and localizations 
of VASH-1 and VASH-2 in this study.  Such differences 
in VASH-1 and VASH-2 distributions have also been 
demonstrated in human placental tissue,  where 
VASH-2 was localized mainly in trophoblasts whereas 
VASH-1 was observed in capillaries [40].  Unlike 
VASH-1,  the proangiogenic effect of VASH-2 has been 
shown to be VEGF-A-independent.  For example,  while 
VASH-1 was found to tightly correlate with VEGF-A 
expression in gastric cancer cell lines [24],  there was not 
significant correlation between VASH-2 and VEGF-A 
expression.  Another study also revealed that VASH-2 
expression was scarcely stimulated by the factors that 
induced VASH-1,  including VEGF in endothelial cells 
in vitro [11].  Taken together,  these results suggest a 
novel mechanism of VASH-2 beyond angiogenesis.  
Indeed,  non-angiogenic actions of VASH-2 was shown 
in human serous ovarian adenocarcinoma [22],  where 
it influenced the migration of endothelial cells by affect-
ing the epithelial-to-mesenchymal transition of cells.  
Other malignant cells such as those in ovarian,  gastro-
intestinal and hepatocellular carcinoma cells have also 
been shown to express VASH-2 [23 , 24].  In our present 
study,  VASH-2 immunoreactivity varied within the 
renal tubules,  being stronger in the renal medulla than 
the renal cortex.  In addition,  the tubular VASH-2+ 
scores were significantly higher in the subgroup with 
hypertension,  which was previously suggested to trig-
ger interstitial injury including fibrosis via the renin-an-
giotensin pathway [41].  These findings suggest that the 
renal tubular expression of VASH-2 may reflect some 
alterations of cellular phenotype that accompany tubu-
lar atrophy and interstitial fibrosis during the disease 
progression in CKD.
Nevertheless,  our study did not reveal a correlation 
between tubular VASH-2+ scores and histopathological 
parameters including renal tubular atrophy and intersti-
tial fibrosis.  Considering the fact that our study subjects 
generally had normal renal function (with mean eGFR 
of 69.0 mL/min/1.73 m2) and likely did not have 
advanced CKD,  we speculate that such associations 
may only become apparent in advanced CKD.  
However,  since a renal biopsy is generally not indicated 
in patients with advanced CKD,  we were not able to 
investigate this relationship.  In contrast to the tubular 
VASH-2+ scores,  higher VASH-2+ scores in the VR were 
significantly associated with preserved renal function.  
Although the implication of vascular VASH-2 expres-
sion is not completely understood,  the decreased 
expression of VASH-2 in the VR may reflect vascular 
injury related to renal dysfunction.  Consistent with this 
hypothesis,  the VR have been shown to be the main 
target of iodinated contrast media-induced renal injury 
[42].
In one of our previous studies,  increased plasma and 
urinary VASH-1 levels predicted worse renal outcomes 
in CKD patients [16].  Unfortunately,  since there are no 
established enzyme-linked immunosorbent assays 
(ELISAs) for VASH-2,  we could not measure the 
plasma VASH-2 levels in the present patients with kid-
ney diseases as well as malignancies.  In contrast to 
VASH-1,  which constitutively expresses in endothelial 
cells,  the basal level of VASH-2 expression observed in 
various organs is quite low [21].  The plasma VASH-2 
level is thus expected to be extremely low in humans,  
except for patients with highly VASH-2-expressing 
tumors.
There were several other limitations in this study.  
First,  as a renal biopsy is not indicated in normal 
healthy humans or in advanced CKD patients,  we were 
not able to obtain the ideal controls for comparative 
analyses.  Second,  the total sample size was not suffi-
cient to allow comparisons among the patients with 
various renal disorders.  Third,  we did not fully eluci-
date the mechanisms underlying the relationships 
between VASH-2 expression and some clinical parame-
ters including the plasma glucose level and the eGFR in 
this preliminary exploratory study.  Systematic in vitro 
378 Arata et al. Acta Med.  Okayama　Vol.  71,  No.  5
and in vivo studies using appropriate controls are 
required to further clarify the precise mechanisms of 
VASH-2 action.
In conclusion,  we investigated the renal distribution 
of VASH-2 in patients with kidney disease,  and our 
results demonstrated a positive association between the 
renal tubular VASH-2 immunoreactivity and blood glu-
cose levels,  as well as a positive association between 
vasa recta VASH-2 and the eGFR.  Further studies are 
required to fully understand the mechanisms and 
potential clinical roles of VASH-2 in kidney diseases.
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